Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

NCT00553358 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

455

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

DRUG: Lapatinib
BIOLOGICAL: Trastuzumab
DRUG: Paclitaxel

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]
[object Object]